ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT

1 .- 159 . (canceled)

160 . A method for preventing a decrease in hematopoietic compartment cells in a subject in need thereof, the method comprising administering a composition comprising a PTD-MYC fusion protein to the subject.

161 . The method of claim 160 , wherein the hematopoietic compartment cells comprise hematopoietic stem cells.

162 . The method of claim 160 , wherein the decrease in hematopoietic compartment cells is due to chemotherapy or radiation therapy.

163 . The method of claim 162 , wherein the composition is to be administered prior to chemotherapy or radiation therapy.

164 . The method of claim 163 , wherein the composition is to be administered about 24 hours prior to the chemotherapy or radiation therapy.

165 . The method of claim 163 , wherein the composition is to be administered about 48 hours prior to the chemotherapy or radiation therapy.

166 . The method of claim 162 , wherein the composition is to be administered prior to and following the chemotherapy or radiation therapy.

167 . The method of claim 166 , wherein the composition is to be administered about 24 hours following chemotherapy or radiation therapy.

168 . The method of claim 161 , wherein the decrease in hematopoietic compartment cells is due to a bone marrow failure syndrome.

169 . The method of claim 168 , wherein the bone marrow failure syndrome is aplastic anemia or Gulf War syndrome.

170 . The method of claim 168 , wherein the bone marrow failure syndrome is an inherited bone marrow failure syndrome (IBMFS).

171 . The method of claim 170 , the IBMFS is selected from amegakaryocytic thrombocytopenia, Diamond-Blackfan anemia, dyskeratosis congenita, fanconi anemia, Pearson syndrome, severe congenital neutropenia, Shwachman Diamond syndrome, and thrombocytopenia absent radii, IVIC syndrome, WT syndrome, radio-ulnar synostosis, and ataxia pancytopenia.

172 . The method of claim 161 , wherein the composition prevents a decrease in the endogenous HSCs.

173 . The method of claim 161 , wherein the PTD-MYC fusion protein is a TAT-MYC fusion protein.

174 . The method of claim 161 , wherein the PTD-MYC fusion protein is to be administered at a dose of at least 0.1 mg/kg, at least 0.2 mg/kg, at least 0.3 mg/kg, at least 0.4 mg/kg, at least 0.5 mg/kg, at least 0.6 mg/kg, at least 0.7 mg/kg, at least 0.8 mg/kg, at least 0.9 mg/kg, at least 1 mg/kg, at least 2 mg/kg, at least 3 mg/kg, at least 4 mg/kg, at least 5 mg/kg, at least 6 mg/kg, at least 7 mg/kg, at least 8 mg/kg, at least 9 mg/kg, at least 10 mg/kg, at least 20 mg/kg, at least 30 mg/kg, at least 40 mg/kg, or at least 50 mg/kg of the subject's weight.

175 . The method of claim 161 , wherein the subject has cancer.

176 . The method of claim 161 , wherein the subject has a hematological malignancy, a myeloma, multiple myeloma, a leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, a lymphoma, indolent lymphoma, non-Hodgkin lymphoma, diffuse B cell lymphoma, follicular lymphoma, mantle cell lymphoma, T cell lymphoma, Hodgkin lymphoma, a neuroblastoma, a retinoblastoma, Shwachman Diamond syndrome, a brain tumor, Ewing's Sarcoma, a Desmoplastic small round cell tumor, a relapsed germ cell tumor, a hematological disorder, a hemoglobinopathy, an autoimmune disorder, juvenile idiopathic arthritis, systemic lupus erythematosus, severe combined immunodeficiency, congenital neutropenia with defective stem cells, severe aplastic anemia, a sickle-cell disease, a myelodysplasia syndrome, chronic granulomatous disease, a metabolic disorder, Hurler syndrome, Gaucher disease, osteopetrosis, malignant infantile osteopetrosis, heart disease, HIV, or AIDS.

177 . The method of claim 161 , wherein the subject is a human subject.

178 . A method of accelerating hematopoietic compartment reconstitution after hematopoietic stem cell (HSC) transplantation in a subject, the method comprising:

a) administering a therapeutically effective amount of a first composition comprising HSCs to achieve hematopoietic compartment reconstitution in a subject in need thereof; and

b) administering a second composition comprising a PTD-MYC fusion protein to the subject,

wherein administering the second composition achieves an acceleration in hematopoietic compartment reconstitution compared to hematopoietic compartment reconstitution in a subject that is not administered the second composition.

179 . The method of claim 178 , wherein the a PTD-MYC fusion protein is a TAT-MYC fusion protein.